Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 6 for:    orphazyme

Study of Arimoclomol in Inclusion Body Myositis (IBM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02753530
Recruitment Status : Active, not recruiting
First Posted : April 28, 2016
Last Update Posted : April 25, 2019
Sponsor:
Collaborators:
University of Kansas Medical Center
University College, London
Information provided by (Responsible Party):
Orphazyme

Brief Summary:
Funding Source - FDA OOPD. The purpose of this study is to evaluate the safety and efficacy of the study drug, Arimoclomol in IBM patients.

Condition or disease Intervention/treatment Phase
Inclusion Body Myositis Drug: Arimoclomol Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Actual Study Start Date : August 9, 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021


Arm Intervention/treatment
Experimental: Arimoclomol
Participants will be asked to take 400mg arimoclomol three times a day.
Drug: Arimoclomol
2 200mg pills taken 3 times per day during breakfast, early afternoon and at bedtime

Placebo Comparator: Placebo
Participants will be asked to take 400mg placebo three times a day.
Other: Placebo
2 matched placebo pills to be taken 3 times per day during breakfast, early afternoon and at bedtime




Primary Outcome Measures :
  1. Decline in Inclusion body myositis functional rating scale (IBMFRS) [ Time Frame: Change from Baseline to Month 20 ]
    Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.


Secondary Outcome Measures :
  1. Manual Muscle Testing (MMT) [ Time Frame: Change from Baseline to Month 20 ]
  2. Maximum voluntary isometric contraction (MVICT) of quadriceps [ Time Frame: Change from Baseline to Month 20 ]
  3. Grip and pinch test [ Time Frame: Change from Baseline to Month 20 ]
  4. modified timed up and go (mTUG) [ Time Frame: Change from Baseline to Month 20 ]
  5. 6 minute walk test with 2 minute distance captured [ Time Frame: Change from Baseline to Month 20 ]
  6. Health Assessment Questionnaire (HAQ-DI) [ Time Frame: Change from Baseline to Month 20 ]
  7. SF-36 [ Time Frame: Change from Baseline to Month 20 ]
    Measured using the Short form health survey with 36 items (SF-36).

  8. Count of adverse events [ Time Frame: Change from Baseline to Month 20 ]
  9. Decline in Inclusion body myositis functional rating scale (IBMFRS) [ Time Frame: Change from Baseline to Month 12 ]
    Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meet any of the European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 2011 categories for IBM
  • Demonstrate being able to arise from a chair without support from another person or device
  • Able to ambulate at least 20 ft/6 meters with or without assistive device. Once arisen from the chair, participant may use any walking device, i.e. walker/frame, can, crutches, or braces. They cannot be supported by another person and cannot use furniture or wall for support.
  • Body weight of >= 40 kg
  • Pre-menopausal women must have a negative pregnancy tst prior to dosing iwht study medication.
  • If a participant in the bimagrumab study, the participant must be off of the study medication for at least 6 months.
  • Able to give informed consent

Exclusion Criteria:

  • History of any of the following excludes subject participation in the study: chronic infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer less than five years prior; or other chronic serious medical illnesses.
  • Presence of any of the following on routine blood screening: WEB <3000; platelets < 100,000; hematocrit , 30%; BUN > 30 mg%; creatinine > 1.5 mg%; symptomatic liver disease with serum albumin < 3 g/dL.
  • History of most recent creatine kinase >15x the upper limit of normal without any other explanation besides IBM.
  • History of non-compliance with other therapies
  • Use of testosterone except for physiologic replacement doses in case of androgen deficiency. Participants must have documented proof of the androgen deficiency.
  • Coexistence of other disease that would be likely to affect outcome measures.
  • Drug or alcohol abuse within past three months
  • Participation in a recent drug study in the last 30 days prior to the screening visit or use of a biologic agent less than 6 months prior to the screening visit.
  • Women who are lactating or unwilling to use adequate method of birth control who are not surgically sterile. Adequate birth control includes use of intrauterine device, abstinence, or oral contraceptives or a double barrier method, e.g condom plas diaphragm will be necessary for both male and female participants.
  • Participants taking >7.5 mg prednisolone or equivalent or participants on IVIg or other immunosuppressants within the last 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02753530


Locations
Layout table for location information
United States, Arizona
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
United States, California
University of California, Irvine
Irvine, California, United States, 92697
United States, Colorado
University of Colorado School of Medicine
Aurora, Colorado, United States, 80045
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21218
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
University of Rochester
Rochester, New York, United States, 14642
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43221
United States, Texas
Nerve and Muscle Center of Texas
Houston, Texas, United States, 77030
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84112
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
United Kingdom
University College of London
London, United Kingdom, WC1N 3BG
Sponsors and Collaborators
Orphazyme
University of Kansas Medical Center
University College, London
Investigators
Layout table for investigator information
Principal Investigator: Mazen Dimahckie, MD University of Kansas Medical Center
Principal Investigator: Michael Hanna, MD University College, London

Layout table for additonal information
Responsible Party: Orphazyme
ClinicalTrials.gov Identifier: NCT02753530     History of Changes
Other Study ID Numbers: STUDY00002461
R01FD004809-01A2 ( U.S. FDA Grant/Contract )
First Posted: April 28, 2016    Key Record Dates
Last Update Posted: April 25, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Myositis
Myositis, Inclusion Body
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases